昂立明视胶囊抗白内障的动物试验  

Anti-catarct Animal Test of Anglimingshi Capsules

作　　者：李慈娟 范小兵 韩超 张迪 杨彬[2] 吴晓兰[2] 

机构地区：[1]上海交大昂立生物医药研究所,上海200030 [2]江苏省药物研究所,江苏南京210009

出　　处：《中成药》2001年第3期199-201,共3页Chinese Traditional Patent Medicine

摘　　要：目的 :观察昂立明视胶囊对实验性白内障的预防和治疗作用。方法 :使用D 半乳糖制作大白鼠眼白内障模型 ,检查了昂立明视胶囊对大鼠眼晶体白内障进展、浑浊度、晶体纤维超微结构、MDA、不溶性蛋白和高分子蛋白含量的影响。结果 :服用昂立明视胶囊能有效地延缓受试大鼠白内障的进展 ,降低晶体混浊度 ,减轻D 半乳糖对大鼠晶体纤维超微结构的损伤 ;生化指标也显示该品能降低晶体MDA的含量 ,减轻晶体脂质过氧化损伤 ,降低晶体内不溶性蛋白和高分子量蛋白的含量。结论Objective: To investigate the effects of Anglimingshi Capsules on preventing and treating experimental catarct. Methods: The model of D galactose induced catarct in rats was established. The effects of Anglimingshi Capsules on the catarct advance, lens opacity, lens structure, MDA and the concentrations of disoluble protein and high weight protein of treated rats were examined.Results: Anglimingshi Capsules could delay the advance of catarct, lower lens opacity and lighten the injury of lens structure by D galactose. Anglimingshi Capsules also decreased the concentration of MDA, lightened the injury of lens by lipid peroxidation and decreaseed the concentrations of disoluble protein and high weight protein. Conclusion: The test provided the foundation for application of Anglimingshi capsule.

关 键 词：昂立明视胶囊 白内障 晶体浑浊度 中医药治疗 动物实验 

分 类 号：R276.761[医药卫生—中医五官科学] R285.5[医药卫生—中医学]